AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29017466 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli from uUTI and cUTI
Number of subjects: 485
Study 29017471 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-admission program
Number of subjects: 16
Study 29017605 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative shared care (CSC) intervention program implemented by complementary alternative health providers (CAPs) and primary health care providers (PHCPs)
Number of subjects: 296
Study 29017605 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 296
Study 29017605 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative shared care (CSC) intervention
Number of subjects: 296
Study 29017776 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN XT transcatheter heart valve system
Number of subjects: 46
Study 29017845 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with self-reported DH (n=272) who spent ≥10min eating fruit per sitting (n=46)
Number of subjects: 600
Study 29017845 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with self-reported DH (n=272) who had a drinking habit such as sipping, swishing or holding drinks in the mouth (n=72)
Number of subjects: 600
Study 29017845 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with self-reported DH (n=272) using a soft toothbrush (n=36)
Number of subjects: 600
Study 29017845 — intervention group
Group type: COMPARATOR
Intervention: Frequency of daily toothbrushing
Number of subjects: 600
Study 29017845 — intervention group
Group type: COMPARATOR
Intervention: Dietary acid intake
Number of subjects: 600
Study 29017991 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified Web-based mobile service with wrist-worn physical activity monitor (Polar Active) providing feedback and fitness guidelines.
Number of subjects: 496
Study 29017991 — intervention group
Group type: COMPARATOR
Intervention: Control group with wrist-worn monitor providing only time of day, no feedback.
Number of subjects: 496
Study 29017994 — intervention group
Group type: EXPERIMENTAL
Intervention: BPTrack, a clinical pharmacist-led mHealth intervention for hypertension management, involving home blood pressure monitoring and medication adherence over a 12-week period.
Number of subjects: 25
Study 29017994 — intervention group
Group type: EXPERIMENTAL
Intervention: BPTrack intervention
Number of subjects: 25
Study 29018077 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 0
Study 29018174 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in patients with AF
Number of subjects: 14737
Study 29018174 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP levels in patients without AF
Number of subjects: 14737
Study 29018174 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive value of NT-proBNP for adverse cardiovascular outcomes
Number of subjects: 14737
Study 29018317 — intervention group
Group type: EXPERIMENTAL
Intervention: JAKE® Multimodal Data Capture System
Number of subjects: 0
Study 29018526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 600
Study 29018526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 29018537 — intervention group
Group type: COMPARATOR
Intervention: AMG 811 (6, 20 or 60 mg)
Number of subjects: 56
Study 29018537 — intervention group
Group type: COMPARATOR
Intervention: AMG 811 (20, 60 or 120 mg)
Number of subjects: 56
Study 29018537 — intervention group
Group type: COMPARATOR
Intervention: AMG 811
Number of subjects: 56
Study 29018540 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised diet eliminating foods with positive assay results and allowing foods with negative assay results
Number of subjects: 58
Study 29018540 — intervention group
Group type: COMPARATOR
Intervention: Individualised diet eliminating foods with negative assay results and allowing foods with positive assay results
Number of subjects: 58
Study 29018564 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate
Number of subjects: 0
Study 29018564 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 0
Study 29020217 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine secondary prophylaxis (PSP) for 12 months
Number of subjects: 74
Study 29020217 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PSP follow-up for 1 year
Number of subjects: 74
Study 29020217 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine secondary prophylaxis (PSP)
Number of subjects: 74
Study 29020221 — intervention group
Group type: EXPERIMENTAL
Intervention: High CXCL9 levels in maternal peripheral blood during pregnancy
Number of subjects: 638
Study 29020221 — intervention group
Group type: EXPERIMENTAL
Intervention: High IL-10 levels in maternal blood at delivery
Number of subjects: 638
Study 29020221 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased IL-1β levels in placental blood
Number of subjects: 638
Study 29020260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 3V-FFR group
Number of subjects: 1136
Study 29020260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 3V-FFR
Number of subjects: 1136
Study 29020260 — intervention group
Group type: COMPARATOR
Intervention: High 3V-FFR group
Number of subjects: 1136
Study 29020286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-engraftment Gram-negative bacteremia (GNB) in allo-HSCT
Number of subjects: 2743
Study 29020286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-engraftment Gram-negative bacteremia (GNB) in auto-HSCT
Number of subjects: 2743
Study 29020310 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin prophylaxis
Number of subjects: 344
Study 29020310 — intervention group
Group type: COMPARATOR
Intervention: Other prophylaxis regimens
Number of subjects: 344
Study 29020310 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 344
Study 29020361 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART (Tenofovir plus emtricitabine/lamivudine)
Number of subjects: 2052
Study 29020364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone prophylaxis
Number of subjects: 591
Study 29020364 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT (allo-HSCT)
Number of subjects: 591
Study 29020364 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections caused by resistant bacteria
Number of subjects: 591
Study 29020364 — intervention group
Group type: COMPARATOR
Intervention: Resistance rates
Number of subjects: 591
Study 29020364 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 591
Study 29020367 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX-II strategy
Number of subjects: 454
Study 29020401 — intervention group
Group type: EXPERIMENTAL
Intervention: T2MI patients
Number of subjects: 1548
Study 29020401 — intervention group
Group type: COMPARATOR
Intervention: T1MI patients
Number of subjects: 1548
Study 29020401 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic prediction model for T2MI
Number of subjects: 1548
Study 29020401 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for T2MI
Number of subjects: 1548
Study 29020401 — intervention group
Group type: EXPERIMENTAL
Intervention: Score based on predictors
Number of subjects: 1548
Study 29020583 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir and pibrentasvir for 12 weeks
Number of subjects: 104
Study 29020998 — intervention group
Group type: EXPERIMENTAL
Intervention: High SHMT2 protein expression
Number of subjects: 801
Study 29020998 — intervention group
Group type: EXPERIMENTAL
Intervention: High ASCT2 protein expression
Number of subjects: 801
Study 29021228 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 100
Study 29021813 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterols 800 mg
Number of subjects: 90
Study 29021813 — intervention group
Group type: EXPERIMENTAL
Intervention: Red yeast rice standardized to contain 5 mg monacolins
Number of subjects: 90
Study 29021813 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of phytosterols and red yeast rice
Number of subjects: 90
Study 29023473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Number of subjects: 73
Study 29023494 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 112
Study 29024428 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 53
Study 29025008 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg qd
Number of subjects: 18
Study 29025008 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg bid
Number of subjects: 18
Study 29025008 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol with ICS/LABA
Number of subjects: 18
Study 29025008 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol with ICS/LABA/LAMA
Number of subjects: 18
Study 29025008 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol with ICS/LABA
Number of subjects: 18
Study 29025008 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol with inhaled LAMA (tiotropium) and LABA (formoterol)
Number of subjects: 18
Study 29025008 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol with LABA alone
Number of subjects: 18
Study 29025041 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of myofascial trigger points (TrPs)
Number of subjects: 40
Study 29025041 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread pressure pain sensitivity
Number of subjects: 40
Study 29025041 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanosensitivity of neural tissue
Number of subjects: 40
Study 29025767 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 0
Study 29026685 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib infusion (27 and 56 mg/m2)
Number of subjects: 77
Study 29027127 — intervention group
Group type: EXPERIMENTAL
Intervention: A/BPO + SEM (supplementary patient education material)
Number of subjects: 97
Study 29027127 — intervention group
Group type: COMPARATOR
Intervention: A/BPO + SOCPE + more visits
Number of subjects: 97
Study 29027127 — intervention group
Group type: COMPARATOR
Intervention: A/BPO + SOCPE only
Number of subjects: 97
Study 29027127 — intervention group
Group type: EXPERIMENTAL
Intervention: A/BPO + SEM
Number of subjects: 97
Study 29027127 — intervention group
Group type: COMPARATOR
Intervention: A/BPO + more visits
Number of subjects: 97
Study 29027127 — intervention group
Group type: COMPARATOR
Intervention: A/BPO alone
Number of subjects: 97
Study 29027195 — intervention group
Group type: EXPERIMENTAL
Intervention: abiraterone acetate/prednisone
Number of subjects: 87
Study 29027607 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measure (PRO) for barriers to antiretroviral therapy (ART) adherence
Number of subjects: 31
Study 29027607 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO for 'passive' patients
Number of subjects: 31
Study 29027607 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO for 'misleading' patients
Number of subjects: 31
Study 29027607 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO for 'stoic' patients
Number of subjects: 31
Study 29027607 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO for 'hedonistic' patients
Number of subjects: 31
Study 29027607 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO for 'obsessive' patients
Number of subjects: 31
Study 29027607 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO for 'overburdened' patients
Number of subjects: 31
Study 29027607 — intervention group
Group type: EXPERIMENTAL
Intervention: General PRO recommendations
Number of subjects: 31
Study 29027812 — intervention group
Group type: EXPERIMENTAL
Intervention: Accu-Chek Connect diabetes management system
Number of subjects: 87
Study 29027863 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcontrast FLAIR imaging
Number of subjects: 23
Study 29027863 — intervention group
Group type: COMPARATOR
Intervention: 3D-GRE imaging
Number of subjects: 23
Study 29027863 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAIR as a complementary tool to 3D-GRE
Number of subjects: 23
Study 29028159 — intervention group
Group type: EXPERIMENTAL
Intervention: Human bocavirus 1 (HBoV1) infection confirmed serologically
Number of subjects: 759
Study 29028159 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of respiratory viruses by PCR
Number of subjects: 759
Study 29028159 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of HBoV1-DNA by PCR
Number of subjects: 759
Study 29028159 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of sole HBoV1
Number of subjects: 759
Study 29028159 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute HBoV1 infection in cases with another virus
Number of subjects: 759
Study 29028159 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute HBoV1 infection in sole virus detection
Number of subjects: 759
Study 29028274 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29028662 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool Xpert
Number of subjects: 165
Study 29028662 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine LAM
Number of subjects: 165
Study 29028662 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum/Gastric aspirate Xpert
Number of subjects: 165
Study 29028662 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool Xpert (in severe immunosuppression)
Number of subjects: 165
Study 29028788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg every 3 weeks
Number of subjects: 979
Study 29028802 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7/PPV23
Number of subjects: 132
Study 29028802 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV23 only
Number of subjects: 132
Study 29028802 — intervention group
Group type: EXPERIMENTAL
Intervention: No pneumococcal vaccines
Number of subjects: 132
Study 29028802 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 132
Study 29028802 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 and/or PPV23 immunization
Number of subjects: 132
Study 29028802 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV23 immunization
Number of subjects: 132
Study 29028910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular microdialysis
Number of subjects: 23
Study 29028933 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing at 6 bpm
Number of subjects: 14
Study 29028933 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing at 10 bpm
Number of subjects: 14
Study 29028933 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced breathing at 15 bpm
Number of subjects: 14
Study 29028966 — intervention group
Group type: EXPERIMENTAL
Intervention: STI screening offered to participants
Number of subjects: 214
Study 29028966 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in insertive anal intercourse
Number of subjects: 214
Study 29028966 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in both insertive and receptive anal intercourse
Number of subjects: 214
Study 29028966 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of STI symptoms
Number of subjects: 214
Study 29028966 — intervention group
Group type: EXPERIMENTAL
Intervention: Condomless sex
Number of subjects: 214
Study 29028966 — intervention group
Group type: EXPERIMENTAL
Intervention: Any recent drug use
Number of subjects: 214
Study 29029064 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 1012
Study 29029064 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV
Number of subjects: 1012
Study 29029122 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su (adjuvanted herpes zoster subunit vaccine), 2 doses 2 months apart
Number of subjects: 430
Study 29029122 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su (adjuvanted herpes zoster subunit vaccine)
Number of subjects: 430
Study 29029127 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS vaccine (0.5, 2.5, or 5.0 μg of each of 3 CRM197-glycoconjugates)
Number of subjects: 317
Study 29029127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 29029127 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS vaccine
Number of subjects: 317
Study 29029131 — intervention group
Group type: EXPERIMENTAL
Intervention: AA infusion
Number of subjects: 21
Study 29029131 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 21
Study 29029190 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-1
Number of subjects: 5
Study 29029562 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT) - Helping the Noncompliant Child (HNC) program
Number of subjects: 15
Study 29029833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose (FDG) uptake
Number of subjects: 0
Study 29030346 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD-RS=0/DD- strategy
Number of subjects: 1850
Study 29030346 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD-RS ≤1/DD- strategy
Number of subjects: 1850
Study 29030346 — intervention group
Group type: COMPARATOR
Intervention: D-dimer (DD) test
Number of subjects: 1850
Study 29030361 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 16
Study 29030361 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord samples
Number of subjects: 16
Study 29030383 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive artificial pancreas (AP) system
Number of subjects: 30
Study 29030401 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Genome Sequencing (WGS)
Number of subjects: 41
Study 29030401 — intervention group
Group type: COMPARATOR
Intervention: Multigene Panel Testing
Number of subjects: 41
Study 29030421 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (n=159)
Number of subjects: 301
Study 29030421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=142)
Number of subjects: 301
Study 29030421 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTTLPR polymorphisms
Number of subjects: 301
Study 29030503 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended therapy combining face-to-face problem solving and a smartphone app
Number of subjects: 7
Study 29030503 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended therapy
Number of subjects: 7
Study 29030717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking status (baseline smoking status)
Number of subjects: 0
Study 29031455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 101
Study 29031861 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed nutrition (PDN)
Number of subjects: 30
Study 29031861 — intervention group
Group type: COMPARATOR
Intervention: Treatment team-directed nutrition (TTDN)
Number of subjects: 30
Study 29032136 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 4872
Study 29032136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4872
Study 29033314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) measurement of area stenosis
Number of subjects: 100
Study 29033314 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS measurement of area stenosis
Number of subjects: 100
Study 29033314 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS diameter measurement in nonthrombotic patients
Number of subjects: 100
Study 29033314 — intervention group
Group type: COMPARATOR
Intervention: Venography measurements
Number of subjects: 100
Study 29033369 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Clostridium symbiosum
Number of subjects: 781
Study 29033369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of C. symbiosum and FIT
Number of subjects: 781
Study 29033369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all markers (C. symbiosum, F. nucleatum, FIT, CEA)
Number of subjects: 781
Study 29033369 — intervention group
Group type: COMPARATOR
Intervention: Fusobacterium nucleatum
Number of subjects: 781
Study 29033369 — intervention group
Group type: COMPARATOR
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 781
Study 29033369 — intervention group
Group type: COMPARATOR
Intervention: Carcinoembryonic antigen (CEA)
Number of subjects: 781
Study 29033827 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive sleepiness
Number of subjects: 0
Study 29033827 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer nighttime in bed
Number of subjects: 0
Study 29033896 — intervention group
Group type: EXPERIMENTAL
Intervention: KDT501 treatment for 28 days
Number of subjects: 9
Study 29034366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib combined with chemotherapy
Number of subjects: 0
Study 29034563 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint pacing (MPP)
Number of subjects: 76
Study 29034563 — intervention group
Group type: COMPARATOR
Intervention: Standard biventricular pacing (BVP)
Number of subjects: 76
Study 29035120 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic inhaler sensor
Number of subjects: 35
Study 29035574 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (5-20 mg/day)
Number of subjects: 41
Study 29035939 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-mg olmesartan
Number of subjects: 4447
Study 29035939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4447
Study 29036212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch Healthy Nutrient and Food Score (DHNaFS)
Number of subjects: 2171
Study 29036212 — intervention group
Group type: EXPERIMENTAL
Intervention: Average DHNaFS score over the preceding 41 months
Number of subjects: 2171
Study 29036212 — intervention group
Group type: COMPARATOR
Intervention: Dutch Undesirable Nutrient and Food Score (DUNaFS)
Number of subjects: 2171
Study 29036345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg/day)
Number of subjects: 70
Study 29036630 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of SCNN1A rare variants
Number of subjects: 1906
Study 29036630 — intervention group
Group type: COMPARATOR
Intervention: SCNN1B and SCNN1G rare variants
Number of subjects: 1906
Study 29036630 — intervention group
Group type: EXPERIMENTAL
Intervention: Common variants in SCNN1A (rs11614164, rs4764586, rs3741914)
Number of subjects: 1906
Study 29036630 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor allele of rs4764586
Number of subjects: 1906